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Abstract 
Cutaneous squamous cell carcinomas (cSCC) are among the most common 
and highly mutated human malignancies. Solar UV radiation is the major factor in the 
etiology of cSCC. Whole exome sequencing of 18 microdissected tumor samples 
(cases) derived from SKH-1 hairless mice that had been chronically exposed to solar-
simulated UV (SSUV) radiation showed a median point mutation (single nucleotide 
polymorphism, SNP) rate of 155 per megabase. The majority (78.6%) of the SNPs are 
C.G>T.A transitions, a characteristic UVR-induced mutational signature. Direct 
comparison with human cSCC cases showed high overlap in terms of both frequency 
and type of SNP mutations. Mutations in Trp53 were detected in 15 of 18 (83%) cases, 
with 20 of 21 SNP mutations located in the protein DNA binding domain. Strikingly, 
multiple non-synonymous SNP mutations in genes encoding Notch family members 
(Notch1-4) were present in 10 of 18 (55%) cases. The histopathological spectrum of 
the mouse cSCC that develop in this model resembles very closely the spectrum of 
human cSCC. We conclude that the mouse SSUV cSCC accurately represent the 
histopathological and mutational spectra of the most prevalent tumor suppressors of 
human cSCC, validating the use of this preclinical model for the prevention and 
treatment of human cSCC. 
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Introduction 
Keratinocyte (basal and squamous cell) skin cancers are the most common 
types of human malignancy. Since the 1960s, the average rise in new cases has been 
3-8% per year (1). This trend is projected to continue because of depletion of 
stratospheric ozone, increased exposure to solar radiation, and longer life expectancy. 
Indeed, cutaneous squamous cell carcinomas (cSCC) are rapidly increasing in 
incidence, causing significant morbidity and mortality (2). In the 10-year period from 
2001 to 2011, Scotland has seen a greater than 50% increase in the incidence of cSCC, 
with now around 3,000 new cases diagnosed annually and associated escalating 
healthcare burden and cost (3). In the US, there were estimated 400,000 new cases of 
cSCC diagnosed in 2012 alone (4). It has been suggested that cSCC represent an 
under-recognized health issue, and that deaths from cSCC may be as common as 
deaths from renal and oropharyngeal carcinomas, and melanoma in some parts of the 
USA (4). This is particularly relevant to patients with multiple cSCC tumors, who 
have markedly elevated risks of recurrence and metastasis (5). 
cSCC typically arise in areas of “field change” on the head and neck where 
cumulative ultraviolet radiation (UVR) damage from the sun has induced multiple 
pre-invasive skin lesions. Indeed, UVR is now well recognized as the major factor in 
the etiology of skin cancer (6). Being the most ubiquitous carcinogen in our 
environment, UVR is a complete carcinogen (an initiator and a promoter). The solar 
UV spectrum has two physiologically relevant wavelength components, the shorter 
and more highly energetic UVB (280–315 nm), which damages the epidermis of the 
skin, and the longer and more penetrant UVA (315–400 nm), which reaches the 
underlying dermis. Exposure to solar UVR causes generation of reactive oxygen 
species (ROS), damage to DNA, lipids and proteins, including DNA damage repair 
proteins, inflammation, and immunosuppression (1). Together, these deleterious 
processes contribute to skin photoageing and photocarcinogenesis. 
In addition to being among the most common, cSCCs are among the most 
highly mutated human malignancies, with reported mutation rates of 33-50 per Mb of 
coding sequence (7, 8). Such extraordinarily high mutation burden makes the 
possibility for success of a single-target therapy unlikely and highlights the need for 
development of prevention strategies. To be able to test candidates and develop 
strategies for skin cancer prevention (and/or treatment) agents, it is essential to have a 
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preclinical model that closely recapitulates the development of the human disease. 
One of the most commonly used skin carcinogenesis models is the mutant Harvey-
Ras (Hras(Q61L))-driven papilloma formation induced by topical treatment with the 
carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) as the initiator, followed by 
chronic applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) as the promoter. 
Recently, two independent groups have conducted comprehensive analyses of the 
mutational landscape of the mouse tumors that form in this model, confirming the 
driver mutations in Ras (Hras, Kras and Rras2) genes with a characteristic 
DMBA/TPA signature (i.e. A>T and G>T transversions), which occur in a mutually-
exclusive fashion in ~90% of the tumors (9, 10). Although mutations in other genes 
were also identified, most of them did not have the DMBA signature, suggesting that 
they occur at the later stages during tumor development (9). Whereas the DMBA/TPA 
model constitutes an excellent model for RAS-driven tumors, as demonstrated by the 
significantly overlapping genes between the mouse tumors that form in this model 
and human SCC from cervix (44%), head and neck (35%), esophagus (25%) and lung 
(18%) (9), activating mutations in RAS genes are infrequent (<11%) in human cSCC 
(8). In contrast to human cSCC, the DMBA/TPA-induced mouse tumors carry an 
average of 5.2 mutations per Mb of coding sequence (10). Overall, tumors that arise 
in this model do not represent the extraordinarily high level and broad spectrum of 
mutations that are characteristic of human cSCC.  
A second skin carcinogenesis model uses UVB as the carcinogen. However, 
this model does not reflect sun exposure accurately as the solar UVR that reaches the 
surface of the earth consists predominantly (~95%) of UVA, with only a small (albeit 
more carcinogenic) component of UVB wavelengths. The presence of the UVA 
component is particularly relevant for modelling the development of cSCC in specific 
high-risk populations, including patients that are undergoing chronic life-long 
treatment with thiopurine immunosuppressive and anti-inflammatory drugs, such as 
solid organ transplants recipients and inflammatory bowel disease patients. This is 
because the combination of UVA and the thiopurine metabolites that incorporate into 
DNA of proliferating skin cells is highly mutagenic, causing damage to DNA and 
DNA damage repair proteins (11-13). Indeed, azathioprine treatment photosensitizes 
the human skin to UVA radiation (14), and the skin cancer risk in organ transplant 
recipients is ~100-fold greater compared to the general population (15). 
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To overcome these limitations and build upon the “high-risk” skin 
carcinogenesis model in SKH-1 hairless mice (16, 17), we have developed a model in 
which immunocompetent SKH-1 hairless mice are subjected chronically and 
intermittently to sub-erythemal doses of solar-simulated UVR twice a week for 15 
weeks (18). Irradiation is then discontinued, and tumor development is monitored. 
Although there are no tumor-bearing mice at the end of the period of irradiation, 
essentially all animals develop tumors during the subsequent 15-20 weeks, in the 
absence of further exposure to UVR. By use of this model, we found that genetic or 
pharmacologic upregulation of transcription factor NF-E2 p45-related factor 2 (Nrf2) 
protects against tumor development (18, 19). Importantly, protection was observed in 
both immunocompetent mice as well as in animals receiving chronic 
immunosuppressive therapy with clinically relevant doses of the thiopurine drug 
azathioprine (18). Very recently, a similar model (with a slightly different irradiation 
schedule) was employed by Kim et al. (20) who found that Fyn, a member of the Src 
family of protein tyrosine kinases, acts as a redox sensor in a signal transduction 
cascade induced by exposure to solar-simulated UVR. Using whole exome 
sequencing of genomic DNA isolated from microdissected tumor tissue, we now 
show that the cSCCs that arise in this mouse model accurately represent the 
mutational spectrum of human cSCC.  
Together, these findings imply that the “high-risk” solar-simulated UVR skin 
carcinogenesis mouse model represents a valid model for human cSCC, and justify its 
use for preclinical testing during the drug development process of topical and/or 
systemic agents for the prevention and treatment of human cSCC. Furthermore, such 
testing could be performed on cancer preventive agents, which have UVR-absorbing 
effects (e.g. sunscreens) and are applied during the irradiation period, as well as on 
drug candidates, which act by non-UVR-filtering mechanisms and are applied during 
the tumor development period after cessation of the UV irradiation schedule. 
 
Materials and Methods 
Animals 
The animal experiments were performed according to the rules and regulations 
described in the UK Animals (Scientific Procedures) Act 1986. All experimental 
animals were age-matched and female. The animal study plan was developed after 
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ethical approval was granted (Project Licence 60/5986), and was further approved by 
the Named Veterinary Surgeon and the Director of Biological Services of the 
University of Dundee. SKH-1 hairless mice (initially obtained form Charles River, 
Germany) were bred and maintained in the Medical School Resource Unit of the 
University of Dundee on a 12-h light/ 12-h dark cycle and 35% humidity. Throughout 
the study, the animals had free access to water and pelleted RM1 diet (SDS Ltd., 
Witham, Essex, UK).  
 
Cutaneous carcinogenesis 
Cutaneous carcinogenesis was initiated when the mice were 8-weeks old by 
subjecting the animals chronically twice a week (on Tuesdays and Fridays) for 15 
weeks to solar-simulated UVR (comprised of 2 J/cm2 UVA and 90 mJ/cm2 UVB). 
UVA340 lamps (Q-Lab, Germany) were used as the irradiation source. Irradiation 
from these lamps simulates the solar UVR from 365 nm to the solar cut-off of 295 nm, 
with a peak emission at 340 nm. The radiant dose was quantified with a UVB Daavlin 
Flex Control Integrating Dosimeter, and was further confirmed by use of an external 
radiometer (X-96 Irradiance Meter; Daavlin, Bryan, OH) before and after each 
irradiation session. The mice were placed in clear, bedding-free cages and then 
exposed to UVR. To prevent excessive heating and discomfort to the animals, the 
irradiation unit (Daavlin, Bryan, OH) was equipped with an electrical fan. Tumors 
(defined as lesions >1 mm in diameter) that formed on the dorsal skin were measured 
and mapped once a week.  
 
Sample preparation for whole exome sequencing 
The experiment was terminated and the tumors were collected at 20 weeks 
after completion of the irradiation schedule (i.e., 35 weeks after the onset of 
irradiation). The tumor samples were snap-frozen in liquid N2, and stored at –80°C. 
Normal non-irradiated ventral skin from the same animals was also obtained at the 
same time and stored under identical conditions. This normal skin served as a source 
of matched germline DNA. Laser-capture microdissection was employed to enrich for 
tumor cell populations and prevent contamination by infiltrating inflammatory cells 
using Zeiss Palm Microbeam microscope (Zeiss, UK). Depending on tumor size and 
purity (as estimated by examination of H&E reference slides that were prepared in 
parallel), ~20-90 sections of 8-μm thickness were cut onto 1.0-mm PEN membrane 
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slides. After staining with 0.05% acid fuchsin (Acros Organics, NJ, USA) in distilled 
water and 0.05% toluidine blue O (Acros Organics, NJ, USA) in 70% ethanol, the 
sections were microdissected. Tumor cells were collected into 180 μl ATL buffer 
(Qiagen, Crawley, UK). Genomic DNA was extracted from tumor cells and from 
matched normal skin samples (which were crushed into fine powder under liquid N2) 
using the QIAamp DNA micro kit (Qiagen, Crawley, UK). Exome capture and 
sequencing was performed by Oxford Genome Technology (Begbroke, UK) at a 
sequencing depth of 100x for the tumor DNA, and 50x for the normal skin DNA. 
 
Data analysis 
Raw sequencing reads were aligned to the reference genome (UCSC mm9) 
using Bowtie2, a fast sensitive read alignment software (21). Single Nucleotide 
Variants (SNV) that differed between tumor and normal samples were identified 
using SomaticSniper 1.0.5. with somatic score filter set at 40 (22). Small insertions 
and deletions (INDELs) were called using Platypus, a haplotype-based variant caller 
for next generation sequencing (23). Mutation calls were annotated using SNPEff (24). 
Copy number alterations were estimated from the exome sequencing data using the 
cn.MOPS (Copy Number estimation by a Mixture Of PoissonS’) algorithm (25). 
Matched normal samples processed in the same batch as the tumor samples were used 
as controls to identify sample specific copy number alterations. The mapped reads for 
the exome sequencing have been deposited in the Sequence Read Archive (SRA) 
database (Project Number: PRJNA352449). Mutational signature and statistical 
analyses were performed in R statistical environment (26). 
 
Results and Discussion 
Mouse cutaneous SCC induced by chronic exposure to solar-simulated UVR 
share similar histopathology with human cutaneous SCC 
 The development of cSCC in humans is usually associated with chronic sun 
exposure in early life (27). We therefore subjected mice, beginning at 8 weeks of age, 
chronically, twice a week for 15 weeks, to solar-simulated UVR (comprised of 2 
J/cm2 UVA and 90 mJ/cm2 UVB). At termination of the irradiation schedule, none of 
the animals had developed tumors. However, during the subsequent 20 weeks tumor 
incidence reached 100% of animals. Visual inspection and mapping of the lesions that 
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formed on the irradiated dorsal skin of each mouse revealed multiple tumors of 
variable sizes (Figure 1), with tumor multiplicity being on average of 5 tumors per 
mouse (18, 19). Interestingly, many animals displayed a “field change”, also known 
as “field cancerization” (28), which is a typical representation of the clinical situation. 
This observation implies that, similar to humans, SKH-1 hairless mice develop 
multiple primary cSCC in close proximity arising within histologically dysplastic 
epithelium following chronic intermittent exposure to solar-simulated UVR. 
The histopathological spectrum of the mouse cutaneous squamous cell 
carcinomas (mcSCC) that develop in this model resembles very closely the spectrum 
of human cutaneous squamous cell carcinomas (hcSCC) (Figure 2 and Table 1). All 
lesions show clear evidence of background generally severe epidermal dysplasia, 
often with follicular extension. The lesions group into three main categories: (i) 
actinic keratosis with no definite invasion; (ii) actinic keratosis with probable early 
dermal invasion, and (iii) invasive SCC – all in the moderate- to well-differentiated 
range and some showing extension into the muscle layer. This spectrum of skin 
tumors is in stark contrast with the tumors that form in the DMBA/TPA skin 
carcinogenesis model, which are primarily papillomas. 
 
Somatic point mutations manifest prominent UV signature 
 We performed exome sequencing of 18 microdissected tumor samples (cases) 
derived from our SKH-1 hairless mice that had been chronically exposed to solar-
simulated UVR as described in Materials and Methods. Tumor selection was based 
on size. The size and histopathological characteristics of each individual tumor are 
described in detail in Table 1. Ventral non-irradiated skin from the same animals 
served as a source of matching normal control DNA. The sequencing revealed a 
median point mutation (single nucleotide polymorphism, SNP) rate of 155 mutations 
per megabase with a high of 279 and a low of 12 (Figure 3A and Supplementary 
Table 1). The overwhelming majority of SNPs were identified as C.G>T.A 
transitions (78.6%, Figure 3B), a characteristic UVR-induced mutational signature 
(29), confirming that UVR is the primary cause of mutations in the mcSCC. It is well 
established that exposure to UVR causes formation of cyclobutane dimers and 
pyrimidine-pyrimidone (6-4) photoproducts in DNA that initiate C.G>T.A transitions 
(30-32). Also consistent with a UVR-induced mutational signature, 81.6% of all 
C.G>T.A mutations in the mouse tumors occurred following a pyrimidine base 
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(Figure 3C), indicative of the formation of dipyrimidine cytosine-containing 
oncogenic photoproducts (29). In addition, the sequencing revealed a median short 
insertion and deletion mutation (INDELS) rate of 23.5 per case, including cases 
harboring zero INDELS to cases with as many as 370 INDELS (Supplementary 
Table 2).  
Our results show a remarkably similar mutational signature of the mcSCC to 
the mutational signature previously described in hcSCC (8, 33). Pickering and 
colleagues reported that an average of 75% of the mutational events in human patient 
cases were C>T transitions, and that 85% of these mutations were found at locations 
following a pyrimidine base (33). Similarly, South and colleagues observed that 
~68% of all SNP mutations were C>T transitions in an independent cohort of hcSCC 
samples (8). Critically, direct comparison of these previously analyzed human hcSCC 
cases and our mcSCC tumors showed high overlap in terms of both frequency and 
type of SNP mutations uncovered (Figure 3D).  
The trinucleotide context of the mutation sites identified in the mcSCC show 
strong correlation with those in hcSCC reported by Pickering and co-workers, and by 
South and co-workers, with C > T mutation predominantly occurring around Y(C > 
T)N trinucleotide (Y represents pyrimidine and N represents A / T / G, or C) (Figure 
3E; Supplementary Figure 1). Moreover, similar comparison also revealed high 
correlation in terms of mutation signature between the mcSCC and a UVR associated 
melanoma mouse model (Figure 3F, Supplementary Figure 1).    
 
Copy-number alteration 
Pickering and co-workers reported recurring regions of copy number gain on 
chromosomes 7, 8q, 9q, 14, and 20. To compare the mcSCC to the reported copy 
number alteration in hcSCC, we estimated copy number alteration from our exome 
sequencing data. Recurring (in at least 3 of the 18 tumor samples) regions of copy 
number gains were detected on chromosome 2, 5, 7, 12, 14, 15, and 18 (Table 2, 
Supplementary Table 3). Interestingly, genes located within these regions 
significantly overlapped with those located in the regions of gains (chromosomes 14, 
7, and 8q) reported in hcSCC (Table 2, enrichment p-value < 0.05, hypergeometric 
test). However, regions of loss (chromosomes 5, 6, 9, 11) detected in the mcSCC did 
not significantly overlap with those in hcSCC.  
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Mouse cutaneous SCC share similar gene mutations as human cutaneous SCC 
 Pathway analysis revealed mutations in genes encoding proteins that 
participate in multiple signaling pathways and cellular processes, such as the Jak-Stat 
signaling pathway, the neurotrophin signaling pathway, the adipocytokine signaling 
pathway, T-cell and B-cell receptor signaling pathway, chemokine signaling pathway, 
MAPK signaling pathway, Hedgehog signaling pathway, p53 signaling pathway, 
Notch signaling pathway, cytokine-cytokine receptor interactions, ECM-receptor 
interactions, endocytosis, phagocytosis, melanogenesis, focal adhesion, and 
metabolism. A complete list is shown in Supplementary Table 1. 
Particularly striking was the occurrence of mutations in Trp53 and genes 
encoding multiple family members of the Notch signaling pathway. In hairless mice, 
early studies have linked mutations in Trp53 to exposures to UVB but not to UVA 
radiation (34). More recently, mutations in the TP53 gene as well as the genes that 
encode the NOTCH family of receptors were identified as driver mutations in hcSCC. 
Interestingly, whereas it has long been known that most if not all hcSCCs contain 
mutations in the TP53 gene, it was recently shown that a significant number of hcSCC 
tumors also harbor mutations in NOTCH receptor encoding genes (8), with NOTCH1 
or NOTCH2 loss-of-function mutations being present in ~75% of hcSCCs (35). We 
therefore conducted a detailed analysis on the mutations in Trp53 and Notch genes 
that were detected in our mcSCC tumor samples.  
A total of 21 independent non-synonymous mutations were found in the Trp53 
gene, representing 15 of the 18 (83%) samples sequenced, while 6 out of the 15 
samples contained two or more mutations (Figure 4A). The mutations were centered 
on 19 locations distributed across 5 of the 12 exons of the Trp53 gene. Additionally, 
20 of the 21 SNP mutations are located in the DNA binding domain of the protein, 
suggesting possible loss-of-function consequences. The presence of all of these 
mutations in the mcSCC tumors was validated by Sanger sequencing 
(Supplementary Table 4). 
Mutations in genes encoding the NOTCH family of receptors in hcSCC are 
usually inactivating and are typically found in the EGF repeat domain. To determine 
the frequency and location of mutations in these genes we analyzed all four members 
of the mouse Notch family of receptors (Notch1-4) in the mcSCC tumors. Non-
synonymous SNP mutations in genes encoding the four Notch family members were 
found in 10 of the 18 mcSCC tumors sequenced (~55%, Figure 4B-E). As in the 
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hcSCC tumors, seven of the 16 mutations are located in the region encoding the EGF 
repeat domain of the mouse genes. A total of 6 mutations representing 5 different 
mcSCC tumors were found in Notch1 (Figure 4B), 3 mutations representing 3 
different mcSCC tumors were found in Notch2 (Figure 4C), 5 mutations representing 
4 different mcSCC tumors were found in Notch3 (Figure 4D), and 2 mutations 
representing 2 different mcSCC tumors were found in Notch4 (Figure 4E). We 
validated the presence of all of these mutations in the mcSCC tumors by Sanger 
sequencing (Supplementary Tables 5-8).  
As noted above, loss-of-function mutation in NOTCH1 or NOTCH2 occur in 
~75% of hcSCC (35), and are considered to be an early event in the development of 
hcSCC (8). Such inactivating mutations are consistent with the role of Notch 
signaling in skin, where in contrast to most other tissues, Notch1 negatively regulates 
keratinocyte self-renewal, promotes differentiation and acts as a tumor suppressor 
through a number of cell autonomous as well as non-cell autonomous growth control 
mechanisms (36-41). The high frequency of mutations in Notch1-4 in our mcSCC 
tumors, which often form areas of field cancerization, is in close agreement with a 
recent report showing that in mice, loss of mesenchymal Notch signaling leads to 
field cancerization and multifocal epithelial tumors (42). It was suggested that this 
could be due to the role of Notch in inhibiting activator protein-1 (AP-1)-mediated 
transcription of secreted growth factors, proteases, and extracellular matrix proteins. 
The same study showed that Notch signaling is suppressed in stromal fields adjacent 
to cutaneous premalignant actinic keratosis lesions surgically excised from human 
patients. In addition, persistent suppression of Notch signaling, accompanied by 
enhanced activity of AP-1, is induced in the dermis of human skin explants and 
dermal fibroblast upon exposure to UVA, but not UVB radiation (42), highlighting 
the importance of the UVA component of the solar UVR in the development of cSCC.  
 
Conclusion 
Taken together, data presented in this study show that the skin tumors that 
develop in this mouse model are similar to human cSCC tumors in terms of 
histopathology, mutational characteristics, and UVR-induced mutational signature. 
We conclude that by: (i) using UVR as the carcinogen, (ii) incorporating both the 
UVA and the UVB components of the solar UVR at their natural ratio, and (iii) 
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employing chronic but intermittent irradiation schedule, this mouse skin 
carcinogenesis model has high relevance to the human disease. We propose the use of 
the model for mechanistic studies aiming to further our understanding of cSCC 
development, as well as for testing potential prevention and treatment strategies for 
human cSCC. 
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Figure Legends 
Figure 1. Macroscopic appearance of lesions that form in SKH-1 hairless mice 
following chronic exposure to solar-simulated UVR. Female SKH-1 hairless mice 
were exposed chronically twice a week for 15 weeks to solar-simulated UVR 
(comprised of 2 J/cm2 UVA and 90 mJ/cm2 UVB) beginning at 8 weeks of age. The 
experiment was terminated 20 weeks after the end of the irradiation schedule. 
Examples of typical “field cancerization” of the skin of three animals at termination 
of the experiment (study week 35). 
 
Figure 2. Histopathological spectrum of lesions that form in SKH-1 hairless mice 
following chronic exposure to solar-simulated UVR. (A) Low grade (basal layer) 
epidermal dysplasia in perilesional skin; (B) Typical actinic keratosis with epidermal 
thickening associated with hyper and parakeratosis; (C) “Bowenoid” actinic keratosis 
amounting to carcinoma in situ; (D) higher power (400x) image of the same tumor 
(C) showing severe cytological atypia with loss of cell polarity, single cell 
dyskeratosis (arrow) and mitosis (arrow); (E) invasive SCC; note warty Bowenoid 
actinic keratosis overlying deeply invasive moderately differentiated carcinoma; (F) 
higher power (200x) image of the same tumor (E) showing islands of invasive 
carcinoma with stromal desmoplasia (arrow); (G) early invasion by SCC; (H) higher 
power (200x) image of the same tumor (I); note the irregular budding with a tongue of 
squamous cells extending into stroma (arrow), as well as single cell invasion (arrow); 
(I) invasive SCC abutting a band of skeletal muscle tissue; (J) higher power (200x) 
image of the same tumor (G) showing deep invasion by SCC cells encroaching onto 
skeletal muscle (arrows). 
 
Figure 3. Mutational signature of solar-simulated UVR-induced mcSCC tumors. 
(A) Total number of unique SNPs detected per tumor; the blue line indicates average 
across all tumors. (B) Pie chart of SNP frequencies indicating C>T (beige), C>G 
(purple), C>A (teal), C > T (green) A>T (green), A>G (blue), and A>C (white). (C) 
Frequency of base preceding each unique SNP mutation. (D) Mutation frequency of 
both transitions and transversions from hcSCC sequencing data from Pickering et al. 
(red circles) and South et al. (green circles), and in solar-simulated UVR-induced 
mcSCC tumors from this study (blue triangles). (E) Comparison of trinucleotide 
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context of SNP mutations found in hcSCC reported by Pickering et al. (red dots), 
hcSCC reported by South et al. (green dots), and our mcSCC samples (blue triangles). 
(F) Comparison of trinucleotide context of SNP mutations found in a mouse UV-
induced melanoma model (m-UV, red squares) and our mcSCC samples (blue 
triangles). 
 
Figure 4. Schematic representation of Trp53 and Notch family nonsynonymous 
mutations in solar-simulated UVR-induced mcSCC tumors.  For all genes, exons 
are separated by blue lines starting with exon 1 on the left hand side. Mutations are 
indicated by red lines within the corresponding exons. Tumor case number, cDNA 
base pair change, and corresponding amino acid change are indicated above each 
mutation. Asterisks indicate a change to a stop codon. Numbers below each mutation 
indicate chromosome location. Location of unique non synonymous mutations in 
Trp53 (A), Notch1 (B), Notch2 (C), Notch3 (D), and Notch4 (E). 
 
 
 
 
Table 1. Histopathological characteristics of cutaneous tumors that form in SKH-1 hairless mice following chronic exposure to solar- 
simulated UVR. 
 
Case 
(#) 
Size 
(mm3) 
Histopathological  characteristics 
379 33.5 Invasive moderately differentiated SCC arising from severely dysplastic epidermis; Invasive into muscle 
442 28 Severely dysplastic actinic keratosis extending into multiple hair follicles 
252 472 Invasive moderately differentiated SCC with focal ulceration 
446 56.7 Invasive moderately differentiated SCC arising from severely dysplastic epidermis; Deeply invasive into muscle 
164 18.2 Severely dysplastic actinic keratosis 
873 13.7 Severely dysplastic actinic keratosis 
334 37.9 Invasive well differentiated SCC arising from severely dysplastic epidermis; the invasive tumour has a broad invasive front. 
444 4.6 Severely dysplastic actinic keratosis 
441 21.18 Severely dysplastic actinic keratosis with extension into hair follicles and focal early dermal invasion by SCC 
1310 8.2 Invasive well differentiated SCC arising from severely dysplastic epidermis 
168 9.6 Severely dysplastic actinic keratosis with focal early dermal invasion by SCC 
278 11.9 Invasive moderately differentiated SCC arising from severely dysplastic epidermis 
124 53.2 Invasive moderately differentiated SCC; Invasive close to muscle 
131 25.8 Severely dysplastic actinic keratosis extending into multiple hair follicles 
876 3.6 Severely dysplastic actinic keratosis with focal early dermal invasion by SCC 
134 35.5 Invasive well differentiated SCC arising from severely dysplastic actinic keratosis 
874 20.6 Invasive moderately to well differentiated SCC arising from severely dysplastic epidermis 
272 904 Invasive well differentiated squamous cell carcinoma arising from severely dysplastic epidermis 
 
Table 2. Copy number gain regions found in mcSCC and the corresponding regions and overlapping genes reported in hcSCC 
 
Gain Regions in mcSCC Gain Regions 
reported in 
hcSCC 
Overlapping genes (Official gene symbols, human) 
chr14:3592398-98303604 chr14 GCH1, PNP, TGM1, PTGDR, PTGER2, DAD1, APEX1, CEBPE, BCL2L2, NFATC4, PCK2, 
PABPN1, REC8, CDKN3, PARP2, RNASE6, CNIH1, EFS, IRF9, PRMT5, NEDD8, NRL, PSME1, 
TM9SF1, CGRRF1, FERMT2, TEP1, SUPT16H, IPO4, MDP1, OSGEP, BMP4, CIDEB, AJUBA, 
RNASE1, SLC7A8, TINF2, LRP10, DLGAP5, TOX4, SALL2, C14orf166, ZNF219, HAUS4, 
C14orf119, AP5M1, TMEM55B, METTL3, LTB4R2, RNASE4, OR11H4, RPGRIP1, SLC22A17, 
OTX2, C14orf93, REM2, METTL17, DCAF11, C14orf37, MRPL52, FBXO34, JPH4, PSMB11, 
TTC5, IL25, SOCS4, CMTM5, RNASE11, OR4K5, OR4K2, OR4N5, THTPA, NAA30, TXNDC16, 
CCNB1IP1, RNASE9, RNASE10, SAMD4A, NYNRIN, ARHGEF40, OR6S1, MMP14, LTB4R, 
NDRG2, ACIN1, GMPR2, ADCY4, KHNYN, RAB2B, OR11H6, OR10G3, GPR137C, OXA1L, 
RIPK3, RABGGTA, RNF31, PPP1R3E, DDHD1, LGALS3, GMFB, EXOC5, NID2, GNG2, 
SLC39A2, EMC9, GNPNAT1, STYX, OR4E2, PELI2, NOP9, FITM1, DHRS1, NGDN, MAPK1IP1L, 
ATG14, OR5AU1, SLC35F4, AP1G2, ERO1L, TMEM260, DHRS4, OR4M1, KLHL33, ZFHX2, 
CMA1, PSMB5, WDHD1, CBLN3, ABHD4, CDH24, TSSK4, MYH7, OR4L1, CHD8, OR4K1, ANG, 
HNRNPC, LRRC16B, EDDM3B, RNASE13, CPNE6, TMEM253, OR4K15, RNASE12, PSME2, 
OR10G2, SLC7A7, CTSG, RNASE2, MYH6, OR11G2, OR4N2, GZMH 
chr8q POLR3D 
chr14:3122492-25912484 chr14 C14orf166, NID2, GNG2 
chr14:30432550-47466147 chr14 PTGDR, PTGER2, CDKN3, CNIH1, FERMT2, BMP4, TXNDC16, GPR137C, DDHD1, GMFB, 
GNPNAT1, STYX, ERO1L 
chr14:49992651-78114658 chr14 PNP, TGM1, DAD1, APEX1, CEBPE, BCL2L2, NFATC4, PCK2, PABPN1, REC8, PARP2, 
RNASE6, EFS, IRF9, PRMT5, NEDD8, NRL, PSME1, TM9SF1, TEP1, SUPT16H, IPO4, MDP1, 
OSGEP, CIDEB, AJUBA, RNASE1, SLC7A8, TINF2, LRP10, TOX4, SALL2, ZNF219, HAUS4, 
C14orf119, TMEM55B, METTL3, LTB4R2, RNASE4, OR11H4, RPGRIP1, SLC22A17, C14orf93, 
REM2, METTL17, DCAF11, C14orf37, MRPL52, JPH4, PSMB11, TTC5, IL25, CMTM5, RNASE11, 
OR4K5, OR4K2, OR4N5, THTPA, CCNB1IP1, RNASE9, RNASE10, NYNRIN, ARHGEF40, 
OR6S1, MMP14, LTB4R, NDRG2, ACIN1, GMPR2, ADCY4, KHNYN, RAB2B, OR11H6, OR10G3, 
OXA1L, RIPK3, RABGGTA, RNF31, PPP1R3E, SLC39A2, EMC9, OR4E2, NOP9, FITM1, DHRS1, 
NGDN, OR5AU1, AP1G2, DHRS4, OR4M1, KLHL33, ZFHX2, CMA1, PSMB5, CBLN3, ABHD4, 
CDH24, TSSK4, MYH7, OR4L1, CHD8, OR4K1, ANG, HNRNPC, LRRC16B, EDDM3B,  
RNASE13, CPNE6, TMEM253, OR4K15, RNASE12, PSME2, OR10G2, SLC7A7, CTSG, 
RNASE2, MYH6, OR11G2, OR4N2, GZMH 
chr8q POLR3D 
chr15:51929767-56964852 chr8q NOV, TNFRSF11B, HAS2, ENPP2, DSCC1, SNTB1, MTBP, MED30, SLC30A8, MAL2, COL14A1, 
EXT1, TAF2, COLEC10, DEPTOR, SAMD12, MRPL13 
chr15:76520787-76813255 chr8q RECQL4, C8orf33, MFSD3, C8orf82, ZNF7, ZNF250, ARHGAP39, RPL8, LRRC14, LRRC24, 
ZNF251, GPT 
chr15:55432364-55895042 chr8q SNTB1 
chr15:31348828-40614922 chr8q RPL30, SDC2, FZD6, KLF10, HRSP12, SLC25A32, DCAF13, ODF1, SPAG1, LRP12, RNF19A, 
UBR5, CPQ, LAPTM4B, BAALC, MTDH, DCSTAMP, TSPYL5, OSR2, CTHRC1, DPYS, MATN2, 
KCNS2, SNX31, ANKRD46, GRHL2, PABPC1, POP1, NIPAL2, STK3, VPS13B, NCALD, ERICH5, 
YWHAZ, RRM2B, FBXO43, RGS22, POLR2K, ZNF706 
chr15:40828793-128800223 chr8q PLEC, EIF3E, BAI1, LY6H, NOV, TNFRSF11B, SQLE, TG, TSTA3, LY6D, JRK, EIF3H, WISP1, 
FOXH1, EBAG9, RECQL4, NDUFB9, GPR20, HAS2, PSCA, ENPP2, KHDRBS3, RNF139, ZHX1, 
DSCC1, EXOSC4, ATAD2, BOP1, RHPN1, ST3GAL1, ASAP1, DGAT1, KIFC2, LYNX1, FBXL6, 
TRPS1, EMC2, KIAA0196, ZHX2, ZC3H3, ARC, PHF20L1, FAM49B, SNTB1, SYBU, WDYHV1, 
ENY2, SLURP1, MTBP, C8orf33, DERL1, SHARPIN, NUDCD1, FBXO32, NSMCE2, GSDMD, 
MFSD3, MED30, FAM83A, PPP1R16A, FAM91A1, SLC30A8, MAL2, SLC39A4, FAM83H, 
ZNF623, PKHD1L1, MAPK15, ZFAT, AARD, C8orf82, TBC1D31, TMEM74, RSPO2, ZNF707, 
FAM84B, COL14A1, OC90, EPPK1, TRHR, ZNF7, ANXA13, KCNQ3, PTP4A3, TONSL, KCNV1, 
EEF1D, OXR1, ZNF250, ARHGAP39, DENND3, EXT1, MYC, TAF2, COLEC10, RPL8, TRMT12, 
DEPTOR, CYHR1, ADCK5, LRRC6, ABRA, SAMD12, ADCY8, ANGPT1, GPAA1, RAD21, CPSF1, 
LRRC14, CHRAC1, GRINA, TOP1MT, COL22A1, EFR3A, SCRIB, MROH1, TMEM65, GML, 
HGH1, MAF1, TMEM71, PARP10, CYC1, NDRG1, PYCRL, LY6E, KCNK9, SLC52A2, TATDN1, 
ZFP41, MAFA, CSMD3, VPS28, GSDMC, SLC45A4, HSF1, AGO2, TRAPPC9, NAPRT, SCX, 
LRRC24, ZNF251, MRPL13, OPLAH, THEM6, CYP11B2, SCRT1, CYP11B1, SPATC1, TIGD5, 
HHLA1, GPT 
chr12:75558256-91008747 chr14 SPTB, LTBP2, ARG2, ESR2, DLST, FNTB, MAX, PGF, TGFB3, NUMB, EIF2S1, ERH, PIGH, 
ABCD4, FOS, MED6, ALDH6A1, ALKBH1, PNMA1, BATF, NPC2, TMED10, ZBTB25, POMT2, 
FCF1, ATP6V1D, COQ6, ADCK1, EIF2B2, SLC39A9, PSEN1, VSX2, GSTZ1, AHSA1, PLEK2, 
AREL1, VASH1, ZBTB1, TTLL5, ZFYVE26, SIPA1L1, DCAF4, MPP5, FUT8, FLVCR2, GPATCH2L, 
EXD2, SYNJ2BP, GPHN, ZNF410, NGB, ZFYVE1, C14orf169, IRF2BPL, ACYP1, IFT43,        
JDP2, SLIRP, RPS6KL1, NEK9, CIPC, ISCA2, PLEKHD1, AKAP5, KCNH5, CHURC1, PROX2, 
GPHB5, DCAF5, TMEM229B, GALNT16, ELMSAN1, TMED8, GPX2, SPTLC2, ZC2HC1C, 
ACOT2, SLC10A1, ZFP36L1, ANGEL1, TMEM63C, DNAL1, ENTPD5, VTI1B, C14orf1,       
PTGR2, KIAA0247, PCNX, VRTN, WDR89, ACOT4, ZDHHC22, RAD51B, TTC9, ACTN1, 
MTHFD1, SNW1, SYNE2, RHOJ, SMOC1, SLC8A3, ADAM21, RGS6, HSPA2, ESRRB, PAPLN, 
CCDC176, MAP3K9, PLEKHG3, SYNDIG1L, YLPM1, MLH3, RDH11, SGPP1, RDH12, PLEKHH1, 
CCDC177, DPF3, ACOT1 
chr7 PPP2R5E 
chr12:113121116-119215446 chr14 BRF1, JAG2, MTA1, AKT1, SIVA1, CDCA4, TMEM121, NUDT14, TDRD9, PACS2, PLD4, 
TMEM179, KIF26A, RD3L, ZBTB42, CRIP1, BTBD6, CEP170B, C14orf180, C14orf80, INF2, 
TEX22, ADSSL1, ASPG, C14orf2 
chr7 PTPRN2, VIPR2, NCAPG2, CDCA7L, WDR60, ESYT2, RAPGEF5 
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